Barclays Upgrades Celldex to Overweight, Raises Price Target to $45
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.
Already have an account? Sign in.
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.
Apple is developing a general-purpose AI agent that can browse the web, control apps, and write code, with a possible launch by late 2027.
Blair raised its rating on PYXS following updated Phase 1 results for MICVO, citing 39% response rate, 9.2-month durability, and Phase 3 plans.
Celldex’s Phase 2 trial of barzolvolimab in atopic dermatitis missed key efficacy goals. The company is ending development in eczema while advancing the drug in other indications.
Be the first to know when deals break, stocks move, or biotech headlines hit.